What is he best known for?
The fields of study he is best known for:
- Cancer
- Pathology
- Internal medicine
Philip E. LeBoit spends much of his time researching Pathology, Melanoma, Bacillary angiomatosis, Nevus and Dermatology.
His study in Histopathology, Differential diagnosis, Lymphoma, Mycosis fungoides and Immunohistochemistry is carried out as part of his Pathology studies.
His study in Melanoma is interdisciplinary in nature, drawing from both Fluorescence in situ hybridization, Comparative genomic hybridization and Human genome.
His biological study deals with issues like Bacillary peliosis, which deal with fields such as Angiomatosis, Cat-scratch disease, Bartonella quintana and Virology.
His research investigates the connection between Nevus and topics such as Cytogenetics that intersect with issues in Desmoplasia, HRAS and Tumor progression.
His research in Dermatology intersects with topics in Pseudomelanoma, Pagetoid and Malignancy.
His most cited work include:
- Distinct Sets of Genetic Alterations in Melanoma (2055 citations)
- Scleromyxoedema-like cutaneous diseases in renal-dialysis patients (747 citations)
- Chromosomal Gains and Losses in Primary Cutaneous Melanomas Detected by Comparative Genomic Hybridization (456 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Pathology, Dermatology, Melanoma, Nevus and Mycosis fungoides.
His study ties his expertise on Comparative genomic hybridization together with the subject of Pathology.
He studied Dermatology and Melanocytic nevus that intersect with Dysplastic nevus.
His Melanoma research is multidisciplinary, incorporating elements of Fluorescence in situ hybridization and Papillary dermis.
Philip E. LeBoit regularly ties together related areas like Peripheral T-cell lymphoma in his Mycosis fungoides studies.
Philip E. LeBoit is interested in CD30, which is a field of Lymphoma.
He most often published in these fields:
- Pathology (61.24%)
- Dermatology (32.02%)
- Melanoma (23.03%)
What were the highlights of his more recent work (between 2013-2021)?
- Pathology (61.24%)
- Melanoma (23.03%)
- Dermatology (32.02%)
In recent papers he was focusing on the following fields of study:
His main research concerns Pathology, Melanoma, Dermatology, Nevus and Cancer research.
His studies in Pathology integrate themes in fields like Comparative genomic hybridization, Carney complex and HRAS.
The various areas that he examines in his Melanoma study include Papillary dermis and Rete Ridge.
He combines subjects such as Melanocytic nevus, Biopsy, Lesion and Melanocytic lesion with his study of Dermatology.
His Melanocytic nevus research is multidisciplinary, incorporating perspectives in Conjunctiva and Cutaneous melanoma.
The Cancer research study which covers Oncogene Fusion that intersects with Kinase.
Between 2013 and 2021, his most popular works were:
- Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up (88 citations)
- Activating MET kinase rearrangements in melanoma and Spitz tumours (85 citations)
- NTRK3 kinase fusions in Spitz tumours. (80 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Pathology
Philip E. LeBoit focuses on Pathology, Melanoma, Comparative genomic hybridization, Nevus and Cancer research.
The concepts of his Pathology study are interwoven with issues in Metastasis and HRAS.
His research integrates issues of Dermatology, Fluorescence in situ hybridization and Germline mutation in his study of Melanoma.
His Comparative genomic hybridization research includes elements of Tumor suppressor proteins, BAP1, Germline and Cutaneous Fibrous Histiocytoma.
His work deals with themes such as Carcinogenesis, Dermis and Grading, which intersect with Nevus.
Philip E. LeBoit has included themes like Gene rearrangement, Desmin, Epithelioid cell and Protein kinase A in his Cancer research study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
